Literature DB >> 2466102

Antigenic variation of human RSV strains isolated in Japan.

H Tsutsumi1, K Nagai, K Suga, Y Chiba, S Chiba, S Tsugawa, P L Ogra.   

Abstract

Antigenic variations of respiratory syncytial virus (RSV) strains were analyzed using a collection of nine, seven, two, and one monoclonal antibodies (MAbs), respectively, raised against the fusion protein (F), large glycoprotein (G), nucleoprotein (NP), and phosphoprotein (P) components of the Long strain of RSV. Competitive binding assay by these MAbs demonstrated eight, four, and two distinct epitopes on F, G, and NP components, respectively. Comparison of prototype Long with ten field strains isolated in Sapporo, Japan, during a 9-year period from 1980 to 1988 by radioimmunoprecipitation (RIP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) test revealed four different patterns of reaction to these MAbs. Thus, prototype Long reacted to all 19 MAbs. Six field strains have shown a different reactivity to one of nine anti-F and to one of seven anti-G antibodies (subgroup A). Three of the remaining isolates failed to react with three of nine anti-F and with all of seven anti-G antibodies (subgroup B). One strain (58-104) isolated in 1983 was similar to subgroup A except for a lack of reaction with two anti-G antibodies. All field strains reacted with two anti-NP and one anti-P antibodies. The numbers of altered epitopes in subgroup A were 1/8 and 1/4; in subgroup B, 3/8 and 4/4; and in 58-104, 1/8 and 2/4 on the F and G components, respectively. No other variations have been observed among field isolates tested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466102     DOI: 10.1002/jmv.1890270211

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

2.  Three antigenic variant groups in human respiratory syncytial virus subgroup B isolated in Japan.

Authors:  K Nagai; H Tsutsumi; H Yamazaki; S Pattamadilok; S Chiba
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 3.  Respiratory syncytial virus genetic and antigenic diversity.

Authors:  W M Sullender
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Humulone suppresses replication of respiratory syncytial virus and release of IL-8 and RANTES in normal human nasal epithelial cells.

Authors:  Jun Fuchimoto; Takashi Kojima; Tamaki Okabayashi; Tomoyuki Masaki; Noriko Ogasawara; Kazufumi Obata; Kazuaki Nomura; Satoshi Hirakawa; Naoyuki Kobayashi; Tatsuro Shigyo; Shin-ichi Yokota; Nobuhiro Fujii; Hiroyuki Tsutsumi; Tetsuo Himi; Norimasa Sawada
Journal:  Med Mol Morphol       Date:  2013-02-05       Impact factor: 2.309

5.  Genetic variability and molecular epidemiology of respiratory syncytial virus subgroup a strains in Japan determined by heteroduplex mobility assay.

Authors:  Yuki Kuroiwa; Kazushige Nagai; Lisa Okita; Hiroyuki Tsutsumi
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

6.  Respiratory syncytial virus subgroup B dominance during one winter season between 1987 and 1992 in Vancouver, Canada.

Authors:  E Thomas; M J Margach; C Orvell; B Morrison; E Wilson
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

7.  Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection.

Authors:  H Yamazaki; H Tsutsumi; K Matsuda; K Nagai; P L Ogra; S Chiba
Journal:  Clin Diagn Lab Immunol       Date:  1994-07

8.  Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus.

Authors:  K Matsuda; H Tsutsumi; Y Okamoto; C Chiba
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

9.  A nuclear factor-κB signaling pathway via protein kinase C δ regulates replication of respiratory syncytial virus in polarized normal human nasal epithelial cells.

Authors:  Tomoyuki Masaki; Takashi Kojima; Tamaki Okabayashi; Noriko Ogasawara; Tsuyoshi Ohkuni; Kazufumi Obata; Akira Takasawa; Masaki Murata; Satoshi Tanaka; Satoshi Hirakawa; Jun Fuchimoto; Takafumi Ninomiya; Nobuhiro Fujii; Hiroyuki Tsutsumi; Tetsuo Himi; Norimasa Sawada
Journal:  Mol Biol Cell       Date:  2011-05-11       Impact factor: 4.138

10.  Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections.

Authors:  Tamaki Okabayashi; Hiroaki Kariwa; Shin-ichi Yokota; Shigeo Iki; Tomokazu Indoh; Noriko Yokosawa; Ikuo Takashima; Hiroyuki Tsutsumi; Nobuhiro Fujii
Journal:  J Med Virol       Date:  2006-04       Impact factor: 2.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.